Regeneron Pharmaceuticals

REGN · NASDAQ

$807.48+$25.44 (+3.25%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $782.04

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. The company is headquartered in Tarrytown, New York and currently employs 15,410 full-time employees. The firm invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The firm is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Lynozyfic, and others.

Employees: 15,410
Headquarters: Tarrytown, New York
Listed: Apr 2, 1991
Sector: Health Care
Industry: Biotechnology
Website: regeneron.com

Leadership

Regeneron Pharmaceuticals executives
Name	Title	Since	Age
Leonard Schleifer	—	1988	72
George Yancopoulos	—	—	65
Christopher Fenimore	—	—	54
Joseph LaRosa	—	—	66
Daniel Van Plew	—	—	52
Marion McCourt	—	—	65
Andrew Murphy	—	—	67
Jason Pitofsky	—	—	48
Christine Poon	—	—	72
Bonnie Bassler	—	—	62
Michael Brown	—	—	84
N. Anthony Coles	—	—	64
Joseph Goldstein	—	—	84
Kathryn Guarini	—	—	53
Arthur Ryan	—	—	82
David Schenkein	—	—	67
George Sing	—	—	75
Craig Thompson	—	—	72
Huda Zoghbi	—	—	70

Revenue by product and region

Fiscal year ended Dec 31, 2025: $14.34B total revenue

By product

Collaboration revenue$7.33B51.1%
Net product sales$6.31B44.0%
Other revenue$702.60M4.9%

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Regeneron Pharmaceuticals suppliers and customers
Company	Relationship	Country	Correlation
McKesson Corporation MCK	Customer	US	0.67
AmerisourceBergen Corporation ABC	Customer	US	0.67
RCM Technologies RCMT	Supplier	US	0.65
Ono Pharmaceutical	Supplier and customer	JP	0.63
Lantheus Holdings, Inc. LNTH	Supplier	US	0.61
Roche Holding ROG.SW	Supplier and customer	CH	0.60
AstraZeneca AZN.L	Supplier and customer	GB	0.60
Sanofi SAN.PA	Supplier and customer	FR	0.50
Roche Holding AG RHHVF	Customer	—	0.46
Adicet Bio, Inc. ACET	Supplier	US	0.41

Similar companies

Companies in the same industry as Regeneron Pharmaceuticals

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.